# The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

Study · id `cardio:ct-nct02932566` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02932566](<https://clinicaltrials.gov/study/NCT02932566>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02932566

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT02932566. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2019-11-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT02932566, source copy `cardio:ctgov-nct02932566-2020-07-02`, retrieved 2026-10-26)
- Started: 2017-03-02 (actual) (ClinicalTrials.gov record NCT02932566, source copy `cardio:ctgov-nct02932566-2020-07-02`, retrieved 2026-10-26)
- Primary completion: 2019-11-29 (actual) (ClinicalTrials.gov record NCT02932566, source copy `cardio:ctgov-nct02932566-2020-07-02`, retrieved 2026-10-26)
- Completion: 2020-04-29 (actual) (ClinicalTrials.gov record NCT02932566, source copy `cardio:ctgov-nct02932566-2020-07-02`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02932566, source copy `cardio:ctgov-nct02932566-2020-07-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02932566-2020-07-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
- Acronym: PIROUETTE
- Condition: Cardiac Failure
- Intervention (Drug): Pirfenidone
- Intervention (Drug): Placebo
- Lead sponsor: Manchester University NHS Foundation Trust
- Lead sponsor class: OTHER\_GOV
- Collaborator: National Institute for Health Research, United Kingdom
- Collaborator class: OTHER\_GOV
- Collaborator: University of Manchester
- Collaborator class: OTHER
- Collaborator: University of Liverpool
- Collaborator class: OTHER
- Collaborator: Hoffmann-La Roche
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Manchester University NHS Foundation Trust (`cardio:org-manchester-university-nhs-foundation-trust`)
- Registry lists this organization as a collaborator: National Institute for Health Research, United Kingdom (`cardio:org-national-institute-for-health-research-united-kingdom`)
- Registry lists this organization as a collaborator: University of Manchester (`cardio:org-university-of-manchester`)
- Registry lists this organization as a collaborator: University of Liverpool (`cardio:org-university-of-liverpool`)
- Registry lists this organization as a collaborator: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial (`cardio:pubmed-34385704`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone (`cardio:pubmed-35861823`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6763cfbd25b4e27af99619a9f168b286bc439aaef86f579a897c4d31f51bced4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
